Compare IFN & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IFN | BWAY |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 540.6M | 450.8M |
| IPO Year | 1994 | N/A |
| Metric | IFN | BWAY |
|---|---|---|
| Price | $12.03 | $16.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | ★ 209.2K | 144.8K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $309.69 |
| Revenue Next Year | N/A | $26.21 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.84 | $8.59 |
| 52 Week High | $16.60 | $26.63 |
| Indicator | IFN | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 51.71 | 59.22 |
| Support Level | $10.84 | $14.56 |
| Resistance Level | $12.50 | $16.63 |
| Average True Range (ATR) | 0.18 | 0.71 |
| MACD | 0.09 | 0.41 |
| Stochastic Oscillator | 64.86 | 95.83 |
India Fund Inc is an asset management company. The fund's investment objective is long-term capital appreciation, which it seeks to achieve by investing in the equity securities of Indian companies. The company's portfolio is a non-diversified closed-end management investment company across various sectors such as financials, consumer staples, information technology, materials, healthcare, consumer discretionary, industrials, telecommunication services, utilities, and others. Geographically, all the business activity functions through the market of the United States.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.